Efficacy and safety of two simplified regional citrate anticoagulation protocols in intermittent hemodialysis: a randomized crossover trial
Conventional regional citrate anticoagulation (RCA) is effective for patients at high bleeding risk but operationally complex. Simplified RCA (S-RCA) uses calcium-containing dialysate and pre-dialyzer citrate infusion; citrate removal across the dialyzer may nevertheless leave the venous bubble trap insufficiently anticoagulated. We compared S-RCA with a two-stage protocol (TS-RCA) that redistributes part of the citrate dose downstream. In this single-center, open-label, randomized crossover trial, 30 adults with active bleeding or high bleeding risk underwent two 4-hour intermittent hemodialysis sessions, one with each protocol. Effective anticoagulation was defined as completing the planned session with clotting grades < 3 in both the dialyzer and venous bubble trap. Secondary outcomes included circuit survival, component-specific clotting, dialysis adequacy, biochemical changes, and adverse events. All participants completed both periods. Effective anticoagulation occurred in 26/30 TS-RCA and 19/30 S-RCA sessions (86.7% vs. 63.3%; P = 0.063). Session duration was longer with TS-RCA (3.94 ± 0.21 vs. 3.68 ± 0.60 h; mean difference 0.26 h; 95% CI, 0.03 to 0.48; P = 0.027) and venous bubble-trap clotting was less severe ( P = 0.001); dialyzer clotting and dialysis adequacy were comparable. Postdialysis systemic ionized calcium was 1.02 ± 0.11 mmol/L with TS-RCA and 1.08 ± 0.13 mmol/L with S-RCA ( P = 0.031), but the between-protocol difference in within-session change was not significant ( P = 0.054). Five hypoglycemic events occurred with each protocol, and one hypotensive event occurred with S-RCA. No serious citrate-related event was observed. TS-RCA showed a favorable but statistically nonsignificant trend toward improved effective anticoagulation versus S-RCA (86.7% vs. 63.3%; P = 0.063). These hypothesis-generating findings suggest a potentially meaningful signal and warrant larger multicenter trials with adequate power. Chinese Clinical Trial Registry, ChiCTR2000034314. Registered on 28 September 2020.
Authors
- Qiudi Tu
- Shizhu Yuan
- Qiang He (ORCID: https://orcid.org/0000-0003-4845-6640)
- Yanqing Jia (ORCID: https://orcid.org/0000-0003-4948-1207)
- Meiling Zhou (ORCID: https://orcid.org/0000-0002-0559-2450)
- Xiaogang Shen (ORCID: https://orcid.org/0000-0003-1738-9430)
- Yueming Liu
- Huajuan Shen (ORCID: https://orcid.org/0009-0004-3644-4866)
Institutions
- Zhejiang Chinese Medical University (CN)
- Affiliated Hospital of Hangzhou Normal University (CN)
- Zhejiang Provincial People's Hospital (CN)
- Shaoxing People's Hospital (CN)
- Hangzhou Medical College (CN)
Publication Details
- Journal
- BMC Nephrology
- Published
- 2026-11-16
- DOI
- https://doi.org/10.1186/s12882-026-05508-6
- Primary Topic
- Dialysis and Renal Disease Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00